More kudos for Cory
30 July, 2002 by Tanya HollisWalter and Eliza Hall Institute director Prof Suzanne Cory has been awarded a Royal Society medal in recognition of her work into the molecular basis for cancer.
Market forces: do biotechs list too early?
26 July, 2002 by Georgina DunnWhat's the difference between a biotech and a dot com? The average age of the board or directors. Funny? Maybe, but not exactly accurate. While there may be a sense of déjà vu - small start-ups looking for cash stampeding to the market - the biotech industry, unlike dot coms, is anything but an overnight phenomenon.
Mass spectrometry: the supply side
26 July, 2002 by Iain ScottIn the last 10 years, we've seen a dizzying array of new variations of mass spectrometry instruments, and at the same time as we've seen radical changes in scientific discovery. Mass spectrometry has become a key tool across the life sciences, from discovery to routine lab work. Consequently there seems to be an almost limitless range of permutations of mass spec.
Where have all the young minds gone?
24 July, 2002 by Melissa TrudingerThe decision to pursue post-doctoral studies overseas is one of the defining moments in a young Australian scientist's career.
Biotechs missing out on tax perk: E&Y
23 July, 2002 by Tanya HollisSmall to medium-sized biotechnology companies are missing out on an important source of cash by failing to claim the Federal R&D rebate, according to a tax specialist.
Science award nominations closing Friday
22 July, 2002 by Iain ScottNominations for two major Australian science prizes, the Clunies Ross Award and the Unsung Hero of Australian Science, close this Friday.
UTS team takes research to the world
22 July, 2002 by Melissa TrudingerA team of scientists and university administrators from the University of Technology, Sydney, has returned from a world tour that established new contacts and showcased the University's research activities.
Perth-based biotech aims for Singapore listing
22 July, 2002 by Pete YoungPerth life science company Rockeby Biomed is expanding in several directions simultaneously.
Bio conference success: it's all in the planning
17 July, 2002 by Melissa TrudingerA post-Bio 2002 debriefing session organised by AusBiotech and the BioMelbourne Network this week had one big message for future delegations - planning, planning, planning.
Diatranz denies trans-Tasman plans
17 July, 2002 by Tanya HollisA New Zealand company working on a pig-derived cure for type 1 diabetes has denied reports of a planned move to Australia.
Red tape hampering Sirtex at home
17 July, 2002 by Pete YoungThe US is embracing Sirtex Medical's novel anti-cancer technology more quickly than Australia where government evaluation of the technology appears to have stalled.
Circadian appoints all-rounder to board
16 July, 2002 by Tanya HollisAustralian biomedical research developer Circadian Technologies has appointed an accountant with a diverse business background to its board.
BresaGen revamps board ahead of strategy refocus
16 July, 2002 by Tanya HollisA board reshuffle aimed at sharpening the focus of Adelaide biotherapy company BresaGen is underway. The company has announced the resignations of three board members and the appointment of an existing director to the chairman's position.
New Zealand feature: NZ lures high-flying Scot to head biotech
12 July, 2002 by Iain ScottSimilarities between New Zealand and Scotland are plentiful - the agrarian industries, the scenery, the weather. But one of the less heralded similarities is the two places' biotechnology industries - or at least, it was, before Scotland's received a major boost about four years ago.
New Zealand feature: solid biotech is lacking investors
12 July, 2002 by Tanya HollisIn terms of industry size, New Zealand and Australia have a similar number of biotech companies operating on their respective shores.
